Home›Trial›NCT05745883
NCT05745883Phase 1ACTIVE NOT RECRUITING

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

Study Summary

This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.

Conditions
Chronic Kidney DiseasesAnemia of Chronic Kidney Disease
Interventions / Drugs
DISC-0974Placebo
View on ClinicalTrials.gov ↗
Sponsor
IRON
Disc Medicine
Hematology
C53/100
Study Details
Enrollment50 participants
Primary Completion—
Lead SponsorDisc Medicine, Inc
Data Retrieved2026-04-11 04:18:08.225355+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 50 participants
Sponsor Catalyst Profile

Disc Medicine (IRON) is the sponsoring company for this trial. BiotechSign currently grades this company C (53/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

IRON Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.